Aquinox Pharmaceuticals (NASDAQ:AQXP) issued its quarterly earnings data on Monday. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10), Yahoo Finance reports.
Aquinox Pharmaceuticals (NASDAQ AQXP) traded down $0.78 during mid-day trading on Tuesday, hitting $15.59. 40,003 shares of the company were exchanged, compared to its average volume of 116,977. Aquinox Pharmaceuticals has a 52-week low of $10.02 and a 52-week high of $17.42. The stock has a market cap of $388.35, a PE ratio of -8.19 and a beta of -14.95.
AQXP has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Tuesday, January 9th. Canaccord Genuity set a $22.00 price target on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, December 19th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $28.00 price target on shares of Aquinox Pharmaceuticals in a research note on Sunday, February 11th. Guggenheim initiated coverage on shares of Aquinox Pharmaceuticals in a research note on Thursday, February 8th. They set a “buy” rating and a $26.00 price target for the company. Finally, BidaskClub raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. Aquinox Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $22.80.
TRADEMARK VIOLATION WARNING: This news story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://sportsperspectives.com/2018/03/13/aquinox-pharmaceuticals-aqxp-posts-earnings-results.html.
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.